| COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF NS Gray, Z Li, J Che, T Zhang US Patent App. 18/549,127, 2024 | | 2024 |
| Small molecule myristate inhibitors of bcr-abl and methods of use NS Gray, J Zhang, B Okram, X Deng, JW Chang, A Wojciechowski US Patent App. 18/421,738, 2024 | | 2024 |
| Author Correction: Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF S Radko-Juettner, H Yue, JA Myers, RD Carter, AN Robertson, P Mittal, ... Nature 629 (8012), E12, 2024 | | 2024 |
| Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof NS Gray, T Zhang, NP Kwiatkowski, M Fan, J Che, W Lu US Patent App. 18/000,049, 2024 | | 2024 |
| Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry S Ke, F Dang, L Wang, JY Chen, MT Naik, W Li, A Thavamani, N Kim, ... Nature Communications 15 (1), 3220, 2024 | 3 | 2024 |
| Inhibitors of EGFR and/or HER2 and methods of use JM Hatcher, NS Gray, J Jaebong, D De Clercq, P Janne, JA Saxon, M Eck, ... US Patent 11,945,816, 2024 | | 2024 |
| Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF S Radko-Juettner, H Yue, JA Myers, RD Carter, AN Robertson, P Mittal, ... Nature 628 (8007), 442-449, 2024 | | 2024 |
| Tricyclic kinase inhibitors and uses thereof NS Gray, T Zhang, Y Liu, D Weinstock, LSM Li US Patent App. 17/766,520, 2024 | | 2024 |
| Rewiring EWS/FLI1 with transcriptional chemical inducers of proximity (TCIPs) MJ Bond, RP Golden, RC Sarott, G DiGiovanni, BA Karim, B Howard, ... Cancer Research 84 (6_Supplement), 5777-5777, 2024 | | 2024 |
| Compounds for tau protein degradation NS Gray, SJ Haggarty, CAI Quan, T Zhang, FM Ferguson US Patent App. 18/200,950, 2024 | | 2024 |
| Small molecule myristate inhibitors of Bcr-abl and methods of use NS Gray, J Zhang, B Okram, X Deng, JW Chang, A Wojciechowski US Patent 11,932,646, 2024 | | 2024 |
| Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof NS Gray, T Zhang, B Jiang, NP Kwiatkowski US Patent 11,932,625, 2024 | | 2024 |
| Sulfonamide derivatives for protein degradation NS Gray, E Fischer, H Yoon, T Zhang, T Faust, K Donovan, CAI Quan, Z Li US Patent App. 18/375,003, 2024 | | 2024 |
| The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma HC Lantermans, F Ma, A Kuil, S van Kesteren, S Yasinoglu, G Yang, ... Leukemia, 1-11, 2024 | | 2024 |
| Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation EC Erickson, I You, G Perry, A Dugourd, KA Donovan, C Crafter, ... Science Signaling 17 (825), eadf2670, 2024 | 1 | 2024 |
| Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality Z Li, J Jiang, SB Ficarro, TS Beyett, C To, I Tavares, Y Zhu, J Li, MJ Eck, ... ACS Central Science, 2024 | | 2024 |
| ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases Z Li, W Lu, TS Beyett, SB Ficarro, J Jiang, J Tse, AYJ Kim, JA Marto, J Che, ... Journal of Medicinal Chemistry, 2024 | 1 | 2024 |
| Map kinase kinase (mkk7) inhibitors and uses thereof NS Gray, SP Treon, J Wang, L Tan, G Yang US Patent App. 17/802,896, 2024 | | 2024 |
| Uses of pyrimidopyrimidinones as SIK inhibitors DE Fisher, N Mujahid, R Murakami, NS Gray, Y Liang, HG Choi US Patent 11,878,019, 2024 | | 2024 |
| Discovery of Potent Antimalarial Type II Kinase Inhibitors with Selectivity over Human Kinases L Wang, MJ Bohmer, J Wang, F Nardella, J Calla, M Laureano De Souza, ... Journal of Medicinal Chemistry 67 (2), 1460-1480, 2024 | | 2024 |
